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8VHIXOQHVV RI&DUGLDF %LRPDUNHU 6FRUH IRU 5LVN 6WUDWLILFDWLRQ LQ
6WDEOH 3DWLHQWV 8QGHUJRLQJ (OHFWLYH &DUGLDF (YDOXDWLRQ $FURVV
*O\FHPLF 6WDWXV
:+ :LOVRQ 7DQJ 0' 1DYHHG ,TEDO 0' <XSLQJ :X 3K' DQG6WDQOH\/ +D]HQ0'3K'

*ODSFBTJOHMZ  DBSEJBD CJPNBSLFST IBWF QSPWJEFE JNQPSUBOU
JOGPSNBUJPOJO QSFEJDUJOHTIPSUUFSNBOE MPOHUFSNSJTLQSPGJMFT
JO QBUJFOUT ZLWK BDVUFDPSPOBSZ TZOESPNFT QBSUJDVMBSMZ XIFO
VTFE JO DPNCJOBUJPO 4FWFSBM DMJOJDBMMZ BWBJMBCMF DBSEJBD
CJPNBSLFST  JODMVEJOH #UZQF OBUSJVSFUJD QFQUJEF #/1 
NZFMPQFSPYJEBTF .1  BOE IJHITFOTJUJWJUZ $SFBDUJWF
QSPUFJO IT$31  QSPWJEF JODSFNFOUBM QSPHOPTUJD WBMVF
JO QBUJFOUT XJUI BDVUF DPSPOBSZ TZOESPNFT  BMPOF PS JO
DPNCJOBUJPO 5IFJS BCJMJUZ UP QSFEJDU DBSEJPWBTDVMBS SJTL IBT
CFFO QPTUVMBUFE  BT UIFZ SFGMFDU VOEFSMZJOH CJPNBSLFST PG
NZPDBSEJBM EZTGVODUJPO  QMBRVF WVMOFSBCJMJUZ  BOE TZTUFNJD
JOGMBNNBUJPO  SFTQFDUJWFMZ ϱ )PXFWFS  UIF DMJOJDBM VUJMJUZ PG
TVDI CJPNBSLFST TJNVMUBOFPVTMZ JO B TUBCMF  OPOBDVUF QBUJFOU
DPIPSU JT MFTT XFMM FTUBCMJTIFE 8F IZQPUIFTJ[FE UIBU TJNVMUB
OFPVT BTTFTTNFOU PG UIFTF DMJOJDBMMZ BWBJMBCMF DBSEJBD
CJPNBSLFST UP QSPEVDF BSJTL TDPSF DPNQPTFE PGUIF TVNT PG
QPTJUJWF CJPNBSLFST PO UIF CBTJT PG FTUBCMJTIFE DVUPGG
WBMVFT  XPVME QSPWJEF JODSFNFOUBM QSPHOPTUJD JOTJHIU JOUP
QSFEJDUJOHGVUVSF BEWFSTFDBSEJPWBTDVMBSPVUDPNFT "TUIFSF JT
BO FWPMWJOH VOEFSTUBOEJOH PG QBUJFOUT XJUI EJBCFUFT BOE
QSFEJBCFUFTCFJOHBUIFJHIUFOFEDBSEJPWBTDVMBSSJTL  XFGVSUIFS
BOBMZ[FE UIF QSPHOPTUJD VUJMJUZ PG UIFTF DBSEJBD CJPNBSLFST
BDSPTTUIFTQFDUSVNPGHMZDFSOJDDPOUSPM
.FUIPET
8F QSPTQFDUJWFMZ FWBMVBUFE   DPOTFDVUJWFMZ DPO
TFOUJOH TVCKFDUT XIP VOEFSXFOU FMFDUJWF DBSEJBD DBUIFUFSJ
[BUJPO SFDSVJUFE GSPN  UP  XJUIPVU FWJEFODF PG
NZPDBSEJBM JOGBSDUJPO DBSEJBD USPQPOJO *  OHNM  "MM
QBSUJDJQBOUT HBWF XSJUUFO JOGPSNFE DPOTFOU  BOE UIF JOTUJUV
UJPOBM SFWJFX CPBSE PG UIF 0FWFMBOE 0JOJD BQQSPWFE UIF
TUVEZ QSPUPDPM 5IF 'SBNJOHIBN SJTL TDPSF XBT DBMDVMBUFE
GPS FBDI TVCKFDU PO UIF CBTJT PG"EVMU 5SFBUNFOU 1BOFM *%
HVJEFMJOFT  "O FTUJNBUF PG DSFBUJOJOF DMFBSBODF XBT DBMDV
MBUFE VTJOH UIF $PDLDSPGU(BVMU FRVBUJPO $PSPOBSZ BSUFSZ

Table 1
Baseline characteristics
Variable

Whole Cohort
(n 3,635)

Diabetes Mellitus
(n 1,014)

Prediabetes
(n 1,529)

Nondiabetes
(n 1,092)

p Value

Age (yrs)
Men
Hypertension
History of myocardial infarction
Systolic blood pressure (mm Hg)
Low density lipoprotein cholesterol (mg/dl)
High density lipoprotein cholesterol (mg/dl)
Creatinine clearance (ml/min/1.73 m2)
Cigarette smoking
Aspirin
b blockers
Angiotensin converting enzyme inhibitors
or angiotensin receptor blockers
Statins
hsCRP (mg/L)
BNP (pg/ml)
MPO (pmol/L)

63  11
65%
71%
33%
133 (120e146)
95 (78e116)
34 (28e41)
100 (76e126)
65%
73%
61%
50%

64  10
61%
78%
35%
134 (120e149)
95 (77e115)
32 (27e39)
99 (74e128)
64%
73%
65%
60%

63  11
70%
70%
32%
132 (120e145)
97 (80e118)
34 (28e42)
100 (77e126)
68%
74%
62%
47%

61  12
64%
62%
32%
132 (119e147)
94 (76e116)
34 (29e42)
100 (79e126)
62%
71%
56%
41%

<0.001
<0.001
<0.001
<0.150
<0.015
<0.012
<0.001
<0.512
<0.002
<0.357
<0.001
<0.001

59%
2.00 (0.91e4.47)
83 (34e200)
103 (70e195)

63%
2.56 (1.13e5.93)
93 (40e240)
105 (74e186)

59%
1.89 (0.86e3.95)
78 (32e177)
104 (69e201)

54%
1.67 (0.83e4.00)
83 (32e198)
100 (68e194)

<0.001
<0.001
<0.001
<0.199

Data are expressed as mean  SD, as percentages, or as median (interquartile range).

Table 2
Cox proportional hazards analyses for individual cardiac biomarker and
future major adverse cardiovascular events at 3 years
Variable

Univariate Model
HR (95% CI)

p Value

Multivariate Model*
HR (95% CI)

p Value

BNP >100 pg/ml 2.76 (2.25e3.39) <0.001 2.10 (1.65e2.68) <0.001
hsCRP >2 ng/L
2.10 (1.71e2.58) <0.001 1.82 (1.46e2.28) <0.001
MPO >322 pmol/L 1.43 (1.12e1.82) <0.004 1.32 (1.02e1.71) <0.036
* Adjusted for age, gender, low density and high density lipoprotein
cholesterol, systolic blood pressure, former or current cigarette smoking,
diabetes mellitus, history of myocardial infarction, and creatinine clearance.

disease was deﬁned as any clinical history of myocardial
infarction, percutaneous coronary intervention, coronary
artery bypass surgery, or angiographic evidence of coronary
artery disease (50% stenosis) in 1 major coronary artery.
Glycemic status and clinical deﬁnition of diabetes mellitus,
“prediabetes,” and nondiabetes were deﬁned by the latest
practice guidelines on the basis of fasting glucose and glycosylated hemoglobin (HbA1c) levels (fasting glucose <100
mg/dl and HbA1c <5.7% for normal subjects; fasting
glucose 126 mg/dl or HbA1c 6.5% or currently taking
glucose-lowering medications for diabetes mellitus; neither
normal nor diabetes mellitus for prediabetes).7 Adjudicated
outcomes were ascertained over the ensuing 3 years for all
subjects after enrollment. The prospective determination of
clinical outcomes was made by the research personnel
contacting participants independent of study investigators,
with prespeciﬁed criteria and conﬁrmation by review of
documentation independent of the investigators. Major
adverse cardiovascular events (MACEs) were deﬁned as
death, nonfatal myocardial infarction, or nonfatal cerebrovascular accident after enrollment. Blood samples were
collected before the administration of heparin, placed on ice,
aliquoted, and frozen at 80 F within 2 hours of collection.

Figure 1. Kaplan Meier analysis of CBS predicting future MACEs at 3 year
follow up.

All laboratory assays, including hsCRP, BNP, MPO,
apolipoprotein A1, apolipoprotein B100, and creatinine,
were performed using the Abbott ARCHITECT ci8200
platform (Abbott Diagnostics Inc., Abbott Park, Illinois).
The intra- and interassay coefﬁcients were 4% and 2.4% for
hsCRP, 2.6% and 3.5% for BNP, and 6.2% and 4.1% for
MPO, respectively.
Student’s t tests or Wilcoxon’s rank-sum tests for continuous variables and chi-square tests for categorical variables
were used to examine the differences between the groups.
A cardiac biomarker score (CBS) was given to each group on
the basis of whether it had a positive value for each respective
biomarker. We used cutoffs for each of the 3 biomarkers
(BNP >100 pg/ml, hsCRP >2.0 ng/L, and MPO >322
pmol/L) on the basis of previous cutoffs used for the respective
markers, as reported in previous studies.2,4,8 Each of the groups
was categorized as 0, 1, 2, or 3 as a measure of how many
biomarkers were deemed positive, which was deﬁned as the
CBS. Kaplan-Meier analysis with Cox proportional-hazards

Table 3
Cox proportional hazards analyses of cardiac biomarker score stratiﬁed by glycemic status
Variable

Whole cohort (n 3,635)
Unadjusted HR
Adjusted HR, model 1 (95%
Adjusted HR, model 2 (95%
MACEs
Normal (n 1,014)
Unadjusted HR
Adjusted HR, model 1 (95%
Adjusted HR, model 2 (95%
MACEs
Prediabetes (n 1,529)
Unadjusted HR
Adjusted HR, model 1 (95%
Adjusted HR, model 2 (95%
MACEs
Diabetes mellitus (n 1,092)
Unadjusted HR
Adjusted HR, model 1 (95%
Adjusted HR, model 2 (95%
MACEs

CBS
0

1

2

3

CI)
CI)

1
1
1
39/955

2.59 (1.82e3.68)*
2.27 (1.59e3.23)*
2.27 (1.59e3.23)*
159/1,549

4.72 (3.33e6.69)*
3.67 (2.58e5.24)*
3.67 (2.58e5.24)*
173/959

7.61 (4.98e11.65)*
6.11 (3.98e9.38)*
6.11 (3.98e9.38)*
47/172

CI)
CI)

1
1
1
13/290

1.78 (0.94e3.37)
1.43 (0.74e2.75)
1.36 (0.7e2.61)
35/445

3.23 (1.69e6.16)*
2.37 (1.21e4.64)*
2.23 (1.14e4.39)*
32/230

6.23 (2.9e13.37)*
4.73 (2.18e10.25)*
4.24 (1.96e9.18)*
13/49

CI)
CI)

1
1
1
15/427

2.74 (1.56e4.84)*
2.4 (1.36e4.23)*
2.37 (1.35e4.19)*
61/654

4.75 (2.7e8.38)*
3.67 (2.06e6.54)*
3.58 (2e6.41)*
61/379

10.27 (5.24e20.13)*
7.87 (3.99e15.55)*
7.62 (3.87e15.01)*
20/69

CI)
CI)

1
1
1
11/238

3.17 (1.67e6)*
3.06 (1.61e5.78)*
3.05 (1.61e5.77)*
63/450

5.59 (2.98e10.49)*
4.79 (2.55e9)*
4.8 (2.55e9.01)*
80/350

6.16 (2.8e13.52)*
5.59 (2.54e12.31)*
5.61 (2.55e12.33)*
14/54

Model 1 was adjusted for traditional risk factors, including age, gender, systolic blood pressure, low density lipoprotein cholesterol, high density lipoprotein
cholesterol, and smoking. Model 2 was adjusted for traditional risk factors plus apolipoprotein B100/apolipoprotein A1 ratio.
* p <0.001.

regression was used for time-to-event analysis to determine
hazard ratios (HRs) and 95% conﬁdence intervals (95%
CIs) for MACEs. Unadjusted trends for all-cause mortality
rates as well as rates of nonfatal myocardial infarction
or stroke with increasing quartiles of MPO, hsCRP, and
BNP were evaluated using the Cochran-Armitage test
using a time-to-event approach. Adjustments were made for
individual traditional cardiac risk factors (including age,
gender, low-density and high-density lipoprotein cholesterol,
systolic blood pressure, former or current cigarette smoking,
diabetes mellitus, apolipoprotein B100/apolipoprotein A1
ratio, history of myocardial infarction, and creatinine
clearance) to predict incident 3-year risk for MACEs. Net
reclassiﬁcation analysis was performed with the 2 Cox
models adjusted for traditional risk factors. Cutoff values for
net reclassiﬁcation index estimation used a ratio of 6:3:1 for
low-, medium-, and high-risk categories. All analyses were
performed using R version 8.02 (R Foundation for Statistical Computing, Vienna, Austria), and p values <0.05 were
considered statistically signiﬁcant.
Results
Table 1 describes the baseline characteristics of our study
population and is stratiﬁed according to glycemic status.
The median levels of hsCRP, BNP, and MPO were
2.00 pg/ml (interquartile range 0.91 to 4.47), 83 pg/ml
(interquartile range 34 to 200), and 103 pmol/L (interquartile range 70 to 195), respectively. All 3 biomarkers
were notably elevated in patients with diabetes compared to
those with prediabetes or nondiabetes.
Table 2 represents the prognostic value of individual
cardiac biomarkers in our study cohort. All 3 cardiac

biomarkers provided incremental risk prediction in our
study cohort. After adjusting for traditional risk factors,
including Framingham risk factors, log-transformed BNP,
hsCRP, and MPO each remained independent predictors of
incident MACEs at 3-year follow-up.
By summing the number of positive cardiac biomarkers,
we developed a CBS that integrated the risk proﬁle of our
study cohort. As illustrated in Figure 1, the CBS provided
incremental prognostic value, as displayed by Kaplan-Meier
analysis. As listed in Table 3, the CBS, based on the sum
total of positive biomarkers, provided independent prediction of future risk for incident MACEs at 3 years (HR 7.61,
95% CI 4.98 to 11.65, p <0.001), even after adjustment for
traditional risk factors (HR 6.11, 95% CI 3.98 to 9.38,
p <0.001), in addition to apolipoprotein B100/apolipoprotein A1 ratio (HR 6.11, 95% CI 3.98 to 9.38, p <0.001)
(Table 3). The ability of the CBS to provide incremental risk
stratiﬁcation can be seen in subgroups of patients with
primary and secondary prevention, as well as those with
maximal coronary artery stenoses <50% and 50%
(Figure 2). A higher CBS predicted future risk for MACEs
at 3 years regardless of age, gender, body mass index, diabetes mellitus, hypertension, renal insufﬁciency, or previous
myocardial infarction (p <0.01 for all). Use of the CBS on
top of traditional risk factors was also shown to reclassify
subjects (net reclassiﬁcation index 12.86%, p <0.001;
integrated discrimination improvement 12.0%, p <0.001;
C-statistic 66.9% vs 71.1%, p <0.001).
We further analyzed our study cohort according to glycemic status and different subgroups. The capability of the
CBS to stratify patients’ risk proﬁles within subjects with
diabetes mellitus, prediabetes, or normal glycemic status
(neither prediabetes nor diabetes) on the basis of practice

Discussion

Figure 2. Forest plot of unadjusted and adjusted HRs for predicting future
MACEs at 3 year follow up according to CBS according to subgroups (zero
score as reference, adjustments as in Table 3, model 1).

Figure 3. Event rates for future MACEs at 3 year follow up according to
glycemic status.

guidelines7 remained robust (Table 3, Figure 3). In a similar
manner, after adjustment for HbA1c, the prognostic value of
the CBS was preserved. Furthermore, the prognostic value
of the CBS was similar regardless of age, gender, body mass
index, diabetes mellitus, hypertension, renal insufﬁciency,
or previous myocardial infarction (p <0.01 for all).

Although previous studies have examined similar multimarker strategies for risk prediction, many of them used
biomarkers that are not commonly used or available in the
clinical practice settings. The key ﬁnding in this study is the
incremental prognostic value of all 3 clinically available
plasma cardiac biomarkers beyond standard evaluation of
classic Framingham risk factors, renal function, and apolipoprotein B100/apolipoprotein A1 ratio in troponin-negative,
stable cardiac patients who undergo coronary angiography.
We further identiﬁed comparable prognostic value within
subsets of patients with prediabetes or nondiabetes or those
with no signiﬁcantly obstructive coronary artery disease,
further underscoring the potential for a multimarker approach
in identifying vulnerable patients within cohorts that may
allow targeted risk factor modiﬁcations and more aggressive
preventive interventions.
HsCRP is the most common systemic inﬂammatory
biomarker used in clinical practice, particularly in patients
with diabetes mellitus and potential response to statin
therapy.4,9 11 Elevated levels have also been associated
with altered cardiac structure and function, as well as
adverse long-term consequences.12 In addition, hsCRP has
been suggested to play a role in atherosclerosis and its
complications, although genetic studies suggest that the
association with adverse outcomes may not be causal.13,14
In contrast, MPO has been shown to directly promote the
catalytic consumption of nitric oxide, leading to the development of endothelial dysfunction.15 17 MPO is a leukocyte-derived hemoprotein that has been linked in the
development and subsequent instability of atherosclerotic
plaques.18,19 Previous studies have shown MPO to have
prognostic signiﬁcance in subjects with unstable angina, as
well as after acute myocardial infarction, acute heart failure,
and chronic stable heart failure, as well as healthy middleaged and elderly subjects.3,18,20 23 Recently, it was also
found that MPO remained a statistically signiﬁcant prognostic indicator of cardiovascular risk in a large stable CAD
population.8 In contrast, the natriuretic peptide family is
a group of endogenous peptides primarily produced in the
heart that provide counter-regulatory effects on a wide range
of organs to maintain perfusion and reduce overloading
status of the vasculature.24 BNP has recently been shown to
be elevated in acute coronary syndromes without necessarily
having myocardial infarction, and it may reﬂect not only the
underlying impairment of left ventricular function but also
the severity of the ischemic episode.25 Altogether, this
combination of biomarkers offers complementary mechanistic insights during cardiac evaluation in stable patients,
although only a small subset of patients demonstrated
positive results for all 3 biomarkers in our relatively stable
patient cohort.
Our study further explored the impact of glycemic
control on the prognostic value of cardiac biomarkers,
particularly as the latest guidelines have highlighted a subset
of “at-risk” patients that is thought to have heightened risk
for developing diabetes mellitus and future cardiovascular
risk.7,26 We observed a graded increase in the levels of each
of our corresponding biomarkers as patients were determined to have nondiabetes, prediabetes, and diabetes. The

overall trend toward increased risk for MACEs was similar
among all groups on the basis of their CBS. Similarly, the
CBS provided signiﬁcant prognostic value among subjects
for whom no signiﬁcant angiographic evidence of stenosis
was discovered, who are most often considered to have
lower risk.
The strength of this study is the considerable size of the
patient population. This contemporary cohort of stable
cardiac patients is representative of current clinical practice.
The focus on the homogenous elective coronary angiography
population and the availability and inclusion of only
biomarkers cleared by the United States Food and Drug
Administration for the analyses strengthen the study, as the
present biomarkers, although clinically available for use, are
not routinely measured. Including them in the analysis
provides insight into a nonacute, troponin-negative population, which has yet to be thoroughly investigated. Incremental contributions of these cardiac biomarkers toward risk
stratiﬁcation above and beyond standard clinical and
biochemical characteristics in this population have also not
been thoroughly tested, particularly with rigorous statistical
evaluation or covariate adjustments. Potential weaknesses of
the study population arise because a clinical trial cohort of
patients who underwent coronary angiography was used, and
thus resulting in, particularly because they were already
undergoing cardiac evaluation. Moreover, our data relate to
prognostic rather than diagnostic applications of these
biomarkers. We also did not have high-sensitivity troponin
assays in this cohort, which was deemed troponin negative by
currently approved troponin assays. Last, although our results
were based on previously used cut points, they may overestimate the strengths of the risk relations. With different
studies using different cutoff values for different populations, there is a need to identify clinically useful cut points
on the basis of consensus of results.
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